4 well as others [83, 84] indicating that the preeclamptic de- cidua contains an excess of macrophages [82]. 7. Summary To date, no accurate test exists for predicting PE. In recent years, it has become accepted that early-onset and late-onset PEs are associated with diﬀerent biochemical, histological, and clinical features [85]. Moreover, markers such as sFLT, sEng, products of fetal and placental origin, markers of renal or endothelial damage, or markers of oxidative stress are sec- ondary to the pathophysiological changes that precede the clinical onset of PE [85]. Nonetheless, a combination of markers may increase the detection accuracy earlier in the pregnancy and hopefully allow for more eﬀective prophylac- tic strategies. References [1] E. J. Roccella, “Report of the national high blood pressure education program working group on high blood pressure in pregnancy,” American Journal of Obstetrics and Gynecology, vol. 183, no. 1, pp. S1–S22, 2000. [2] ACOG Committee on Practice Bulletins–Obstetrics, “ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002,” Obstetrics and Gynecology, vol. 99, pp. 159–167, 2002. [3] F. Milne, C. Redman, J. Walker et al., “The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community,” British Medical Journal, vol. 330, no. 7491, pp. 576–580, 2005. [4] B. M. Sibai, “Magnesium sulfate prophylaxis in preeclampsia: lessons learned from recent trials,” American Journal of Obstetrics and Gynecology, vol. 190, no. 6, pp. 1520–1526, 2004. [5] C. J. Berg, A. P. MacKay, C. Qin, and W. M. Callaghan, “Overview of maternal morbidity during hospitalization for labor and delivery in the united states: 1993–1997 and 2001– 2005,” Obstetrics and Gynecology, vol. 113, no. 5, pp. 1075– 1081, 2009. [6] C. L. Ogden, M. D. Carroll, L. R. Curtin, M. A. McDowell, C. J. Tabak, and K. M. Flegal, “Prevalence of overweight and obesity in the United States, 1999–2004,” Journal of the American Medical Association, vol. 295, no. 13, pp. 1549–1555, 2006. [7] J. M. Catov, R. B. Ness, K. E. Kip, and J. Olsen, “Risk of early or severe preeclampsia related to pre-existing conditions,” International Journal of Epidemiology, vol. 36, no. 2, pp. 412– 419, 2007. [8] L. Duley, “Pre-eclampsia and the hypertensive disorders of pregnancy,” British Medical Bulletin, vol. 67, pp. 161–176, 2003. [9] K. S. Khan, D. Wojdyla, L. Say, A. M. G u¨lmezoglu, and P. F. Van Look, “WHO analysis of causes of maternal death: a systematic review,” Lancet, vol. 367, no. 9516, pp. 1066–1074, 2006. [10] J. A. Lykke, J. Langhoﬀ-Roos, B. M. Sibai, E. F. Funai, E. W. Triche, and M. J. Paidas, “Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother,” Hypertension, vol. 53, no. 6, pp. 944– 951, 2009. [11] J. M. Roberts and C. A. Hubel, “The two stage model of preeclampsia: variations on the theme,” Placenta, vol. 30, pp. S32–S37, 2009. Journal of Pregnancy [12] E. A. P. Steegers, P. von Dadelszen, J. J. Duvekot, and R. Pijnenborg, “Pre-eclampsia,” The Lancet, vol. 376, no. 9741, pp. 631–644, 2010. [13] R. J. Levine, C. Lam, C. Qian et al., “Soluble endoglin and other circulating antiangiogenic factors in preeclampsia,” New England Journal of Medicine, vol. 355, no. 10, pp. 992–1005, 2006. [14] P. Vuorela, S. Helske, C. Hornig, K. Alitalo, H. Weich, and E. Halmesmaki, “Amniotic ﬂuid—soluble vascular endothelial growth factor receptor-1 in preeclampsia,” Obstetrics & Gyne- cology, vol. 95, pp. 353–357, 2000. [15] A. Rajakumar, H. M. Michael, P. A. Rajakumar et al., “Extra- placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women,” Placenta, vol. 26, no. 7, pp. 563–573, 2005. [16] S. E. Maynard, J. Y. Min, J. Merchan et al., “Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction hypertension, and proteinuria in preeclampsia,” Journal of Clinical Investigation, vol. 111, no. 5, pp. 649–658, 2003. [17] W. P. Mutter and S. A. Karumanchi, “Molecular mechanisms of preeclampsia,” Microvascular Research, vol. 75, no. 1, pp. 1– 8, 2008. [18] S. Baumwell and S. A. Karumanchi, “Pre-eclampsia: clini- cal manifestations and molecular mechanisms,” Nephron— Clinical Practice, vol. 106, no. 2, pp. c72–c81, 2007. [19] S. Venkatesha, M. Toporsian, C. Lam et al., “Soluble endoglin contributes to the pathogenesis of preeclampsia,” Nature Medicine, vol. 12, no. 6, pp. 642–649, 2006. [20] J. S. Gilbert, M. J. Ryan, B. B. Lamarca, M. Sedeek, S. R. Murphy, and J. P. Granger, “Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothe- lial dysfunction,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 294, no. 2, pp. H541–H550, 2008. [21] S. A. Karumanchi and M. D. Lindheimer, “Preeclampsia pathogenesis: “Triple a rating”—-autoantibodies and antiAn- giogenic factors,” Hypertension, vol. 51, no. 4, pp. 991–992, 2008. [22] A. Wang, S. Rana, and S. A. Karumanchi, “Preeclampsia: the role of angiogenic factors in its pathogenesis,” Physiology, vol. 24, no. 3, pp. 147–158, 2009. [23] B. T. Zhu, “Catechol-O-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and kenobiotics: impor- tance in pathophysiology and pathogenesis,” Current Drug Metabolism, vol. 3, no. 3, pp. 321–349, 2002. [24] S. L. Mooberry, “Mechanism of action of 2-methoxyestradiol: new developments,” Drug Resistance Updates, vol. 6, no. 6, pp. 355–361, 2003. [25] N. J. Mabjeesh, D. Escuin, T. M. LaVallee et al., “2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF,” Cancer Cell, vol. 3, no. 4, pp. 363–375, 2003. [26] K. Kanasaki, K. Palmsten, H. Sugimoto et al., “Deﬁciency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia,” Nature, vol. 453, no. 7198, pp. 1117–1121, 2008. [27] F. Barchiesi, E. K. Jackson, D. G. Gillespie, L. C. Zacharia, J. Fingerle, and R. K. Dubey, “Methoxyestradiols mediate estradiol-induced antimitogenesis in human aortic SMCS,” Hypertension, vol. 39, no. 4, pp. 874–879, 2002.